# AMPH catalysts: Amphastar Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/amph/catalysts

> Amphastar Pharmaceuticals, Inc. (AMPH) has no upcoming catalysts in this calendar. The latest recorded is the Amphastar Pharmaceuticals, Inc. earnings report, November 5, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Amphastar Pharmaceuticals, Inc. |
| Ticker | AMPH (Nasdaq) |
| SEC CIK | 1297184 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/amph |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 17, 2017 | [Rezenopy (naloxone hydrochloride) complete response letter (CRL)](https://sec-api.dev/pdufa/naloxone) | AMPH |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22208969_2023_Orig1s000OtherActionLtrs.pdf%22)) |
| February 27, 2025 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718425000003/amph-20250227xex99d1.htm)) |
| May 7, 2025 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718425000025/amph-20250507xex99d1.htm)) |
| August 7, 2025 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718425000048/amph-20250807xex99d1.htm)) |
| November 6, 2025 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718425000062/amph-20251106xex99d1.htm)) |
| Dec 2025 | [Forteo® (teriparatide) FDA approval](https://sec-api.dev/pdufa/teriparatide) | AMPH |  | completed, approved | "In December 2025, the FDA approved our teriparatide injection, USP 560mcg/2.24mLsingle-patient-use prefilled pen, which we launched in the December 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm)) |
| February 26, 2026 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000007/amph-20260226xex99d1.htm)) |
| February 26, 2026 | [We complete response letter (CRL)](https://sec-api.dev/pdufa/we) | AMPH |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761403_20260226.pdf%22)) |
| May 7, 2026 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000031/amph-20260507xex99d1.htm)) |
| June 22, 2026 | [I004 primary completion](https://sec-api.dev/pdufa/i004) | AMPH | Pharmacokinetics; Pharmacodynamics; Insulin Aspart | completed | "NCT07560150 (Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-06-22 (ACTUAL); Lead Sponsor Amphastar Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07560150)) |
| August 6, 2026 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000045/amph-20260806xex99d1.htm)) |
| November 5, 2026 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000051/amph-ex99d1.htm)) |

## Drugs

- [I004](https://sec-api.dev/pdufa/i004): Pharmacokinetics
- [We](https://sec-api.dev/pdufa/we): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/amph/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AMPH catalysts: Amphastar Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/amph/catalysts

```bibtex
@misc{secapidev_companies_amph_catalysts_20261116,
  title        = {AMPH catalysts: Amphastar Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/amph/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_amph_catalysts_20261116","title":"AMPH catalysts: Amphastar Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/amph/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
